Adamis Pharmaceuticals Corp
Company Snapshot: Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. In its specialty pharmaceutical pipeline, ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.
- Aug 14 2019 Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary
- Aug 8 2019 Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update
- Aug 5 2019 Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update
- Aug 1 2019 Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
- Jul 31 2019 Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants